Stock comparison
Abbott Laboratories
IDEXX Laboratories
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
ABT
Abbott Laboratories
Market cap
$152.25B
Sector
Healthcare
IDXX
IDEXX Laboratories
Market cap
$44.12B
Sector
Healthcare
Overall winner
IDEXX Laboratories IDXX
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | ABT | IDXX | Winner |
|---|---|---|---|
| Warren Buffett | 61C | 75B | IDXX |
| Benjamin Graham | 69B | 80A | IDXX |
| Philip Fisher | 46D | 75B | IDXX |
| Peter Lynch | 24F | 71B | IDXX |
| Joel Greenblatt | 42D | 83C | IDXX |
| Charlie Munger | 57C | 87A | IDXX |
| Terry Smith | 54D | 84A | IDXX |
Side-by-side metrics
| Metric | ABT | IDXX |
|---|---|---|
| Market cap | $152.25B | $44.12B |
| P/E (TTM) | 23.5x | 39.0x |
| EV/EBIT | 21.7x | 31.6x |
| ROIC (TTM) | 6.56% | 40.66% |
| Gross margin | 56.38% | 62.05% |
| Net margin | 13.91% | 24.63% |
| Revenue CAGR 5y | 0.72% | 7.56% |
| EPS CAGR 5y | -1.48% | 10.79% |
| Debt / Equity | 0.7x | 0.7x |
| Dividend yield | 2.89% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
ABT leads on
- Dividend yield2.89%vs 0.0%+100%
- Market cap$152.25Bvs $44.12B+71%
- P/E (TTM)23.5xvs 39.0x+40%
- EV/EBIT21.7xvs 31.6x+31%
IDXX leads on
- EPS CAGR 5y10.79%vs -1.48%+114%
- Revenue CAGR 5y7.56%vs 0.72%+90%
- ROIC (TTM)40.66%vs 6.56%+84%
- Net margin24.63%vs 13.91%+44%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.